Clinical trials in recurrent ovarian cancer

Michael Friedlander, Edward Trimble, Anna Tinker, David Alberts, Elisabeth Avall-Lundqvist, Mark Brady, Philipp Harter, Sandro Pignata, Eric Pujade-Lauraine, Jalid Sehouli, Ignace Vergote, Philip Beale, Rudd Bekkers, Paula Calvert, Lawrence Copeland, Ros Glasspool, Antonio Gonzalez-Martin, Dionysis Katsaros, Jae Won Kim, Brigitte MillerDiane Provencher, Lawrence Rubinstein, Mostafa Atri, Alain Zeimet, Monica Bacon, Henry Kitchener, Gavin C E Stuart

Research output: Contribution to journalArticlepeer-review


The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?

Original languageEnglish
Pages (from-to)771-775
Number of pages5
JournalInternational Journal of Gynecological Cancer
Issue number4
Publication statusPublished - May 2011


  • Clinical trials
  • Ovarian cancer
  • Recurrent

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology


Dive into the research topics of 'Clinical trials in recurrent ovarian cancer'. Together they form a unique fingerprint.

Cite this